Literature DB >> 34915551

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.

Lu Lu1, Bobo Wing Yee Mok1, Lin Lei Chen1, Jacky Man Chun Chan2, Owen Tak Yin Tsang2, Bosco Hoi Shiu Lam3, Vivien Wai Man Chuang4, Allen Wing Ho Chu1, Wan Mui Chan1, Jonathan Daniel Ip1, Brian Pui Chun Chan1, Ruiqi Zhang5, Cyril Chik Yan Yip1,6, Vincent Chi Chung Cheng1,6, Kwok Hung Chan1, Dong Yan Jin7, Ivan Fan Ngai Hung5, Kwok Yung Yuen1,6, Honglin Chen1, Kelvin Kai Wang To1,6.   

Abstract

BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron variant, designated as a variant of concern by the World Health Organization, carries numerous spike mutations that are known to evade neutralizing antibodies elicited by coronavirus disease 2019 (COVID-19) vaccines. A deeper understanding of the susceptibility of omicron variant to vaccine-induced neutralizing antibodies is urgently needed for risk assessment.
METHODS: Omicron variant strains HKU691 and HKU344-R346K were isolated from patients using TMPRSS2-overexpressing VeroE6 cells. Whole genome sequence was determined using nanopore sequencing. Neutralization susceptibility of ancestral lineage A virus and the omicron, delta and beta variants to sera from 25 BNT162b2 and 25 CoronaVac vaccine recipients was determined using a live virus microneutralization assay.
RESULTS: The omicron variant strain HKU344-R346K has an additional spike R346K mutation, which is present in 8.5% of strains deposited in the GISAID database. Only 20% and 24% of BNT162b2 recipients had detectable neutralizing antibody against the omicron variant HKU691 and HKU344-R346K, respectively, whereas none of the CoronaVac recipients had detectable neutralizing antibody titer against either omicron isolate. For BNT162b2 recipients, the geometric mean neutralization antibody titers (GMTs) of the omicron variant isolates (5.43 and 6.42) were 35.7-39.9-fold lower than that of the ancestral virus (229.4), and the GMTs of both omicron variant isolates were significantly lower than those of the beta and delta variants. There was no significant difference in the GMTs between HKU691 and HKU344-R346K.
CONCLUSIONS: Omicron variant escapes neutralizing antibodies elicited by BNT162b2 or CoronaVac. The additional R346K mutation did not affect the neutralization susceptibility. Our data suggest that the omicron variant may be associated with lower COVID-19 vaccine effectiveness.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19 vaccine; SARS-CoV-2; neutralizing antibody; omicron variant; variant of concern

Mesh:

Substances:

Year:  2022        PMID: 34915551      PMCID: PMC8754807          DOI: 10.1093/cid/ciab1041

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  130 in total

1.  Omicron thwarts some of the world's most-used COVID vaccines.

Authors:  Elie Dolgin
Journal:  Nature       Date:  2022-01       Impact factor: 49.962

2.  Anti-human ACE2 antibody neutralizes and inhibits virus production of SARS-CoV-2 variants of concern.

Authors:  Abigael E Chaouat; Ilija Brizic; Paola Kucan Brlic; Nofar Atari; Limor Kliker; Or Alfi; Michal Mandelboim; Dana Wolf; Laith Tafish; Inbal Kol; Stipan Jonjic; Ofer Mandelboim
Journal:  iScience       Date:  2022-08-13

3.  Investigating COVID-19 Vaccine Impact on the Risk of Hospitalisation through the Analysis of National Surveillance Data Collected in Belgium.

Authors:  Diana Erazo; Maria F Vincenti-Gonzalez; Joris A F van Loenhout; Pierre Hubin; Mathil Vandromme; Piet Maes; Maxime Taquet; Johan Van Weyenbergh; Lucy Catteau; Simon Dellicour
Journal:  Viruses       Date:  2022-06-16       Impact factor: 5.818

Review 4.  Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.

Authors:  Shuai Xia; Lijue Wang; Yun Zhu; Lu Lu; Shibo Jiang
Journal:  Signal Transduct Target Ther       Date:  2022-07-19

5.  Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees.

Authors:  Michael Jäger; Sissy Therese Sonnleitner; Stefanie Dichtl; Eliott Lafon; Gabriel Diem; Gernot Walder; Cornelia Lass-Flörl; Doris Wilflingseder; Wilfried Posch
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

Review 6.  Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Authors:  Cong Sun; Chu Xie; Guo-Long Bu; Lan-Yi Zhong; Mu-Sheng Zeng
Journal:  Signal Transduct Target Ther       Date:  2022-06-28

7.  Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.

Authors:  Rafaella F Q Grenfell; Nathalie B F Almeida; Priscilla S Filgueiras; Camila A Corsini; Sarah V C Gomes; Daniel A P de Miranda; Adelina J Lourenço; Olindo A Martins-Filho; Jaquelline G de Oliveira; Andrea Teixeira-Carvalho; Guilherme R F Campos; Mauricio L Nogueira; Pedro Augusto Alves; Gabriel R Fernandes; Leda R Castilho; Tulio M Lima; Daniel P B de Abreu; Renata G F Alvim; Thaís Bárbara de S Silva; Wander de J Jeremias; Dayane A Otta; Ana Carolina Campi-Azevedo
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 8.  Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity.

Authors:  Jessica R Durkee-Shock; Michael D Keller
Journal:  Ann Allergy Asthma Immunol       Date:  2022-06-16       Impact factor: 6.248

Review 9.  Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review.

Authors:  Karen Cortés-Sarabia; Mayralina Gutiérrez-Torres; Escarlet Maleny Mendoza-Renteria; Marco Antonio Leyva-Vázquez; Amalia Vences-Velázquez; Daniel Hernández-Sotelo; Fredy Omar Beltrán-Anaya; Oscar Del Moral-Hernández; Berenice Illades-Aguiar
Journal:  Vaccines (Basel)       Date:  2022-06-07

10.  Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms.

Authors:  Caroline G Atyeo; Lydia L Shook; Sara Brigida; Rose M De Guzman; Stepan Demidkin; Cordelia Muir; Babatunde Akinwunmi; Arantxa Medina Baez; Maegan L Sheehan; Erin McSweeney; Madeleine D Burns; Ruhi Nayak; Maya K Kumar; Chinmay D Patel; Allison Fialkowski; Dana Cvrk; Ilona T Goldfarb; Lael M Yonker; Alessio Fasano; Alejandro B Balazs; Michal A Elovitz; Kathryn J Gray; Galit Alter; Andrea G Edlow
Journal:  Nat Commun       Date:  2022-06-28       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.